Suppr超能文献

自体脂肪移植和注射用真皮填充剂治疗人类免疫缺陷病毒相关性面部脂肪营养不良:安全性、疗效和长期治疗结果比较。

Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.

机构信息

Washington, D.C. From the Department of Plastic Surgery, Georgetown University Hospital, and DAVinci Plastic Surgery.

出版信息

Plast Reconstr Surg. 2013 Mar;131(3):499-506. doi: 10.1097/PRS.0b013e31827c6df5.

Abstract

BACKGROUND

Facial lipoatrophy is a common side effect of human immunodeficiency virus treatment with highly active antiretroviral therapy. To identify the most clinically durable and efficient way of addressing facial lipoatrophy, the authors reviewed all available evidence for the use of injectable dermal fillers and autologous fat transfers as treatment modalities, focusing on safety, outcomes, and long-term durability.

METHODS

A systematic review of the Cochrane and MEDLINE databases for autologous fat transfer and injectable dermal fillers for the treatment of human immunodeficiency virus-associated lipodystrophy was performed. Based on U.S. Food and Drug Administration approval in human immunodeficiency virus lipoatrophy, studies were limited to the use of hyaluronic acid and/or poly-L-lactic acid. Facial volume, subjective patient satisfaction, standardized outcome scales, reinjection rates, and complications were recorded.

RESULTS

Nineteen studies were included representing 724 patients, with 549 patients in the hyaluronic acid/poly-L-lactic acid cohort and 175 in the autologous fat transfer cohort. Improvements in facial volume and durability of treatment were similar between dermal fillers and fat transfer, as measured by both objective means and subjective patient outcomes. However, poly-L-lactic acid was reinjected at a rate three times that of autologous fat, and was associated with a relatively high rate of subcutaneous papule formation at 22 percent (range, 3 to 44 percent).

CONCLUSIONS

Dermal fillers and autologous fat transfer are effective treatment modalities for human immunodeficiency virus-associated facial lipoatrophy, with high rates of facial volume restoration and patient satisfaction. Autologous fat transfer may offer similar to superior long-term durability but with less of a financial burden compared with injectable fillers.

摘要

背景

面部脂肪萎缩是高效抗逆转录病毒疗法治疗人类免疫缺陷病毒的常见副作用。为了确定解决面部脂肪萎缩最具临床持久性和效率的方法,作者回顾了所有可用于治疗人类免疫缺陷病毒相关性脂肪营养不良的注射用真皮填充剂和自体脂肪转移的证据,重点关注安全性、结果和长期耐久性。

方法

对 Cochrane 和 MEDLINE 数据库中关于自体脂肪转移和注射用真皮填充剂治疗人类免疫缺陷病毒相关性脂肪营养不良的研究进行了系统回顾。根据美国食品和药物管理局对人类免疫缺陷病毒脂肪萎缩的批准,研究仅限于使用透明质酸和/或聚左旋乳酸。记录了面部体积、主观患者满意度、标准化结局量表、再注射率和并发症。

结果

共纳入 19 项研究,代表 724 例患者,其中透明质酸/聚左旋乳酸组 549 例,自体脂肪转移组 175 例。真皮填充剂和脂肪转移在面部体积和治疗持久性方面的改善相似,这两种方法都通过客观手段和主观患者结局进行了测量。然而,聚左旋乳酸的再注射率是自体脂肪的三倍,且与相对较高的 22%(范围 3%至 44%)的皮下丘疹形成率相关。

结论

真皮填充剂和自体脂肪转移是治疗人类免疫缺陷病毒相关性面部脂肪萎缩的有效方法,具有很高的面部体积恢复率和患者满意度。自体脂肪转移可能具有相似或优于注射填充剂的长期耐久性,但经济负担较小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验